Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Persistent Corneal Epithelial Defects Therapeutics Market Size Anticipated to Boost at a CAGR of 18.69% for the Study Period 2018-2030 | DelveInsight

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

12 Oct, 2021, 17:30 GMT

Share this article

Share toX

Share this article

Share toX

The Persistent Corneal Epithelial Defects pipeline therapies expected to get launched in the forecasted period include Nexagon, ST266, RGN-259, REC-0559, and others. These are expected to create a positive shift in the Persistent Corneal Epithelial Defects market during the forecast period (2021-2030).

LAS VEGAS, Oct. 12, 2021 /PRNewswire/ -- DelveInsight's Persistent Corneal Epithelial Defects (PEDs or PCEDs) Market report offers detailed information on current treatment practices, emerging drugs, Persistent Corneal Epithelial Defects market share of the individual therapies, current and forecasted Persistent Corneal Epithelial Defects market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

Some of the key takeaways from the Persistent Corneal Epithelial Defects Market Report:

  • As per DelveInsight's estimate, the total Persistent Corneal Epithelial Defects incident cases in 2020 were reported to be 241,452 in the 7MM.
  • DelveInsight estimates that PCED affects males more as compared to females. 
  • The PCED therapy market space is monopolized by aggressive lubrication, punctal occlusion, bandage soft contact lens, pressure patching, tetracyclines, prophylactic topical antibiotics, and steroids. 
  • The Persistent Corneal Epithelial Defects therapeutic market size appears to be dominated by the United States in 2020, worth USD 83.9 million. 
  • Key pharmaceutical and biotech companies actively engaged in the Persistent Corneal Epithelial Defects market space include OcuNexus Therapeutics, Eyevance Pharmaceuticals, and Noveome Biotherapeutics, among others.
  • The Persistent Corneal Epithelial Defects pipeline therapies expected to launch in the forecasted period (2021-2030) include Nexagon, ST266, RGN-259, REC-0559, and others. The anticipated launch of the pipeline therapies is expected to create a positive shift in the market during the forecast period (2021-2030).
  • Nexagon (OcuNexus Therapeutics, Eyevance Pharmaceuticals) is a first-in-class natural, antisense therapy that downregulates the cell membrane hemichannel forming protein, connexin43 (Cx43).
  • The demand for novel therapies with the absence of key players led to the boosted R&D from the academic-industry partnership that led to the prompting of open innovation and prioritizing the targeting of PED. Novel therapies being investigated recently are beginning to show promise in the treatment of the nonhealing corneal epithelium.

Download Persistent Corneal Epithelial Defects Market Snapshot report to understand which Persistent Corneal Epithelial Defects drug is going to capture the maximum market share @ Persistent Corneal Epithelial Defects Therapy Market Analysis and Forecast 

Persistent Corneal Epithelial Defects: Disease Overview

Persistent Corneal Epithelial Defects (PCED/ PED) are characterized by the failure of the rapid re-epithelialization and closure within 10-14 days after a corneal injury, even with standard supportive treatment. 

 Persistent Corneal Epithelial Defects Epidemiological Segmentation

DelveInsight's Persistent Corneal Epithelial Defects Market Insights Report offers historical as well as forecasted epidemiological analysis during the study period 2018-30 in the 7MM segmented into:

  • Total  Persistent Corneal Epithelial Defects Incident Cases 
  • Gender-specific PCED Incidence 
  • Etiology-specific  Persistent Corneal Epithelial Defects Incidence 

Understand how Persistent Corneal Epithelial Defects Epidemiological Trends are going to shape by 2030 in 7 Major Markets by downloading @ Persistent Corneal Epithelial Defects Epidemiology Market Report Summary

Present PCED Therapeutics Market Outlook 

The current approaches include aggressive lubrication, punctal occlusion, bandage soft contact lens, pressure patching, tetracyclines, prophylactic topical antibiotics, and steroids. Membrane grafting, autologous serum, scleral contact lenses, and others are available for relapse cases. Persistent epithelial defects of the cornea can be challenging to even the experienced ophthalmologist. 

Although several therapies exist and an increasing number of novel approaches are emerging, treatment of PEDs can still be quite challenging. It is essential to treat the underlying causative condition, including infection, limbal stem cell deficiency, or diabetes, to facilitate wound healing. In individuals with PCEDs, there is a high risk of infection or further injury resulting in permanent vision loss due to corneal scarring, infection, neovascularization, and incomplete wound healing. The current PCED therapy market has several unmet needs in the form of a lack of adequate and curative therapies that can heal or reverse the damage to the cornea. 

PCED Market: Unmet Needs and Forecasted Scenario

Several pharmaceutical and biotech companies such as OcuNexus Therapeutics, Eyevance Pharmaceuticals, Noveome Biotherapeutics, RegeneRx Biopharmaceuticals, and several others are working to keep the market growth steady, showcasing an encouraging future picture. 

DelveInsight estimates that with an entry of pharmaceutical pharma players and the expected launch of novel therapies, the futuristic outlook of the PCED market is anticipated to be promising during the next decade. Besides, a better understanding of the condition of increased healthcare expenditure and funding from international organizations shall further add to the growth of the Persistent Corneal Epithelial Defects market share. 

Know which therapy is expected to score the touchdown first @ Persistent Corneal Epithelial Defects Therapeutic Pipeline and Market Forecast

Persistent Corneal Epithelial Defects Pipeline Therapies in focus in the report analysis

  • Nexagon: OcuNexus Therapeutics
  • ST266: Noveome Biotherapeutics
  • RGN-259: RegeneRx Biopharmaceuticals
  • REC-0559: Recordati Rare Diseases/Mimetech

Learn more about available treatments @ Persistent Corneal Epithelial Defects Drug Pipeline Therapies 

Persistent Corneal Epithelial Defects Market Dynamics

Persistent Corneal Epithelial Defects Market to grow due to rising prevalence and increased awareness about the PED and its association with other diseases and its detection. Identifying potential targets, orphan designations, market exclusivity, support from various organizations are attracting the companies to develop novel therapies, which may increase the future Persistent Corneal Epithelial Defects market growth.

Nevertheless, the growth of the Persistent Corneal Epithelial Defects Market may be hindered by the poor response rate and various side effects of the available treatment option. Also, stringent regulatory procedures by regulatory authorities on medication and devices are hampering the persistent epithelial defects treatments market.

Discover more about the future market share of the therapies @ Persistent Corneal Epithelial Defects Treatment Market Landscape and Forecast 

Scope of the Persistent Corneal Epithelial Defects Market Report 
Coverage: 7MM (the US, EU5, and Japan)
Study Period: 2018-30
Key Companies: OcuNexus Therapeutics, Eyevance Pharmaceuticals, Noveome Biotherapeutics, RegeneRx Biopharmaceuticals, and several others. 
Key Persistent Corneal Epithelial Defects Pipeline Therapies: Nexagon, ST266, RGN-259, REC-0559, and several others. 
Persistent Corneal Epithelial Defects Market Segmentation: By Geography, By Persistent Corneal Epithelial Defects Therapies
Analysis: Comparative and conjoint analysis of Persistent Corneal Epithelial Defects Emerging Therapies
Tools used: SWOT analysis, Conjoint Analysis, Porter's Five Forces, PESTLE analysis, BCG Matrix analysis methods.
Case Studies
KOL's Views
Analyst's Views

Drop by to learn more about the future market trends @ Persistent Corneal Epithelial Defects Market Landscape and Forecast 

Table of Contents 

1

Key Insights

2

 Executive Summary of Persistent Corneal Epithelial Defects

3

Persistent Corneal Epithelial Defects Market Overview at a Glance

4

Organizations

5

Competitive Intelligence Analysis for Persistent Corneal Epithelial Defects

6

Persistent Corneal Epithelial Defects Disease Background and Overview

7

Persistent Corneal Epithelial Defects Epidemiology and Patient Population

8

Treatment Algorithm, Current Treatment, and Medical Practices

9

Persistent Corneal Epithelial Defects Epidemiology and Patient Population

10

Country Wise Epidemiology of Persistent Corneal Epithelial Defects

11

Persistent Corneal Epithelial Defects Treatment 

12

Access and Reimbursement Overview of PCED

13

Persistent Corneal Epithelial Defects Emerging Therapies

14

Persistent Corneal Epithelial Defects: 7 Major Market Analysis

15

Persistent Corneal Epithelial Defects Market Unmet Needs 

16

PCED Market Drivers

17

Persistent Corneal Epithelial Defects Market Barriers

18

Bibliography

19

SWOT Analysis

20

KOL Reviews

21

Appendix

22

DelveInsight Capabilities

23

Disclaimer

24

About DelveInsight

Get in touch with our Business executive for Rich and Deep Market Assessment and Consulting Solutions 

Related Reports 

Severe Hypertriglyceridemia Market 
DelveInsight's "Severe Hypertriglyceridemia (SHTG) Market Insights, Epidemiology, and Market Forecast-2030" report.

Smoking Cessation And Nicotine Addiction Market 
DelveInsight's "Smoking Cessation and Nicotine Addiction Market Insights, Epidemiology, and Market Forecast-2030" report. 

Uveal Neoplasms Market 
DelveInsight's "Uveal Neoplasms Market Insights, Epidemiology, and Market Forecast-2030" report. 

Uveitis Market
DelveInsight's 'Uveitis-Market Insights, Epidemiology, and Market Forecast–2030' report. Key companies working in this domain are Sirion Therapeutics, Novartis, Valeant Pharmaceuticals International Inc, Aldeyra Therapeutics, Santen, EyeGate Pharmaceuticals, and others.

Varicose Veins Market 
DelveInsight's "Varicose Veins Market Insights, Epidemiology, and Market Forecast-2030" report. 

Suggested reading

Charcot-Marie-Tooth Disease Market 
Drones in Healthcare Delivery System 
Venous Thromboembolism Market Growth 
Duchenne Muscular Dystrophy Market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. Discover how DelveInsight helped a Europe-based large-cap pharma company assess its pipeline activities and make strategic decisions to outperform in the market through its Pharma and healthcare market competitive benchmarking services.

Contact Us
Shruti Thakur 
info@delveinsight.com  
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

Modal title

Also from this source

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

DelveInsight's GPRC5D-directed Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive...

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

DelveInsight's Sleep Apnea Market Insights report includes a comprehensive understanding of current treatment practices, sleep apnea emerging drugs,...

More Releases From This Source

Explore

Medical Equipment

Medical Equipment

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.